All
Healthy Living May Reduce Risk of Severe Prostate Cancer By Over Half
December 4th 2015Living a healthier lifestyle could be a robust preventative measure against metastatic prostate cancer. One new study suggests that leading a healthy lifestyle could reduce a man's chances of developing the cancer by up to 68%.
Studies Suggest Radical Prostatectomy May Be Optimal in Men With High-Risk Prostate Cancer
December 3rd 2015Recent studies suggest that RP may be a better initial treatment given many of these patients require multimodal therapy to manage their disease. The question about radiation versus surgery lies in the details, with treatment tailored to each patient.
Roll-Your-Own-Tumor Technology for Cancer Research May Boost Personalized Treatments
December 1st 2015Details of a new technology for studying tumor metabolism have been published in Nature Materials, whereby a cellulose strip containing tumor cells was wrapped around a metal core and incubated, mimicking conditions consistent with in vivo tumors.
FDA Hands Down Complete Response Letter for Use of Nivolumab in BRAF-Mutated Melanoma
November 30th 2015The FDA has issued a complete response letter to Bristol-Myers Squibb regarding its supplemental biologics license application for the use of single-agent nivolumab in previously untreated patients with BRAF V600 mutation-positive advanced melanoma.
Advanced Melanoma Responds Well to Pembrolizumab/Ipilimumab Combination
November 25th 2015A regimen of pembrolizumab (Keytruda) and low-dose ipilimumab (Yervoy) was effective, and tolerable, for patients with advanced melanoma, according to results from the phase Ib KEYNOTE-029 clinical trial presented by lead investigator Georgina Long, BSc, PhD, MBBS.
Next-Generation Sequencing in Contralateral Breast Cancer Could Affect Treatment Decisions
November 23rd 2015A new method to elucidate the clonal relationship between tumors used tissues and clinical details from patients with contralateral breast cancer, and for the first time, next-generation sequencing.
Dabrafenib/Trametinib Fully Approved by FDA for BRAF-Mutant Melanoma
November 21st 2015A combination of dabrafenib and trametinib has been approved by the FDA for patients with unresectable or metastatic BRAF-mutated melanoma, based on an extension in overall survival (OS) from two phase III studies.
Ixazomib Approved for Relapsed Multiple Myeloma by FDA
November 20th 2015A combination of the oral proteasome inhibitor ixazomib (Ninlaro), lenalidomide (Revlimid) and dexamethasone has been approved by the FDA a full 4 months ahead of schedule for patients with multiple myeloma with at least 1 prior surgery.
Novel Nanocarrier Could Penetrate Blood-Brain Barrier in Glioblastoma
November 20th 2015A team of scientists have conducted preclinical trials of a novel drug nanocarrier, 3HM, that may offer a solution to breaking the blood-brain barrier in the treatment of brain cancers like glioblastoma multiforme.
Scientists Uncover Potential TMZ-Resistance Reversal in Glioblastoma
November 20th 2015A team of scientists from Virginia Tech Carilion Research Institute and clinicians from Carilion Clinic may have found a way to increase sensitivity to the front-line chemotherapeutic agent temozolomide (TMZ) in glioblastoma (GBM), even after resistance.
Trametinib and Dabrafenib Combo Successful in Melanoma
November 19th 2015Patients receiving a combination of MEK inhibitor trametinib and BRAF inhibitor dabrafenib not only greatly improves long-term outcomes, but also lowers some adverse events associated with either standalone agent for patients with BRAF-mutated metastatic melanoma.
Checkpoint Inhibitors Stir Up Excitement in RCC Treatment
November 19th 2015The treatment paradigm for renal cell carcinoma (RCC) could undergo major changes in the future due to several novel therapies in the works for regulatory approval and checkpoint inhibitors, vaccines, recombinant T-cell receptors, and bi-specific T-cell engagers.